Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

About Kythera Biopharmaceuticals

Kythera Biopharmaceuticals logoKYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: KYTH
  • CUSIP: 50157010
Key Metrics:
  • Previous Close: $74.98
  • 50 Day Moving Average: $74.78
  • 200 Day Moving Average: $62.97
  • 52-Week Range: $29.86 - $76.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -22.72
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Kythera Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Show:
DateFirmActionRatingPrice TargetDetails
6/29/2015Leerink SwannDowngradeOutperform -> Market Perform$61.00 -> $75.00View Rating Details
6/8/2015GuggenheimInitiated CoverageBuy$64.00View Rating Details
4/10/2015Bank of America Corp.Initiated CoverageBuy$66.00 -> $47.00View Rating Details
11/11/2014FBR & CoLower Price TargetOutperform$62.00 -> $59.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015        
8/5/2015Q2($1.15)($1.44)ViewN/AView Earnings Details
5/7/2015Q115($1.12)$1.24ViewN/AView Earnings Details
3/2/2015Q414($1.07)($1.07)ViewN/AView Earnings Details
8/7/2014Q2($0.83)($0.86)ViewListenView Earnings Details
5/8/2014Q1($0.67)($3.18)ViewListenView Earnings Details
3/17/2014Q413($0.69)($0.66)ViewN/AView Earnings Details
11/14/2013Q313($0.72)($0.62)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.70)($0.67)ViewN/AView Earnings Details
5/13/2013Q1 2013($0.97)($0.77)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.76)($1.04)ViewN/AView Earnings Details
11/13/2012Q312($11.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Current Year EPS Consensus Estimate: $-4.45 EPS
Next Year EPS Consensus Estimate: $-3.30 EPS

Dividends

Dividend History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/24/2015Frederick Beddingfield IIIinsiderSell110,638$74.91$8,287,892.58View SEC Filing  
9/24/2015John W. SmitherCFOSell53,835$74.90$4,032,241.50View SEC Filing  
9/23/2015Elisabeth SandovalinsiderSell83,122$74.90$6,225,837.80View SEC Filing  
9/23/2015Keith KleinGeneral CounselSell52,153$74.90$3,906,259.70View SEC Filing  
9/22/2015John W. SmitherCFOSell6,645$74.91$497,776.95View SEC Filing  
9/22/2015Keith KleinGeneral CounselSell10,589$74.90$793,116.10View SEC Filing  
9/18/2015John W. SmitherCFOSell1,054$74.95$78,997.30View SEC Filing  
9/1/2015Camille D SamuelsDirectorSell250$74.72$18,680.00View SEC Filing  
6/25/2015Frederick Beddingfield IIIInsiderSell30,583$75.66$2,313,909.78View SEC Filing  
6/25/2015John W SmitherCFOSell4,600$75.50$347,300.00View SEC Filing  
5/1/2015Keith R LeonardCEOSell13,000$44.93$584,090.00View SEC Filing  
4/30/2015Elisabeth SandovalInsiderSell1,654$45.55$75,339.70View SEC Filing  
4/30/2015John W SmitherCFOSell2,041$45.49$92,845.09View SEC Filing  
4/30/2015Keith R LeonardCEOSell5,557$45.29$251,676.53View SEC Filing  
4/15/2015Keith R LeonardCEOSell2,709$50.52$136,858.68View SEC Filing  
4/1/2015Keith R LeonardCEOSell13,548$48.14$652,200.72View SEC Filing  
3/16/2015Keith R LeonardCEOSell5,312$50.16$266,449.92View SEC Filing  
3/9/2015Nathaniel E DavidDirectorSell6,185$55.00$340,175.00View SEC Filing  
3/5/2015John W SmitherCFOSell4,200$48.09$201,978.00View SEC Filing  
3/5/2015Nathaniel E DavidDirectorSell12,375$48.49$600,063.75View SEC Filing  
3/2/2015Keith R LeonardCEOSell10,625$40.94$434,987.50View SEC Filing  
3/2/2015Nathaniel E DavidDirectorSell1,875$40.78$76,462.50View SEC Filing  
2/18/2015John W SmitherCFOSell2,000$41.00$82,000.00View SEC Filing  
2/17/2015Keith R LeonardCEOSell4,165$40.46$168,515.90View SEC Filing  
2/2/2015Keith R LeonardCEOSell6,249$36.70$229,338.30View SEC Filing  
2/2/2015Nathaniel E DavidDirectorSell1,715$36.76$63,043.40View SEC Filing  
1/29/2015John W SmitherCFOSell1,000$38.00$38,000.00View SEC Filing  
1/23/2015John W SmitherCFOSell3,000$35.65$106,950.00View SEC Filing  
1/16/2015Camille D SamuelsDirectorSell250$36.70$9,175.00View SEC Filing  
1/2/2015Keith R LeonardCEOSell6,120$35.37$216,464.40View SEC Filing  
1/2/2015Nathaniel E DavidDirectorSell1,680$35.30$59,304.00View SEC Filing  
12/1/2014Keith R LeonardCEOSell5,994$37.60$225,374.40View SEC Filing  
12/1/2014Nathaniel E DavidDirectorSell1,645$37.67$61,967.15View SEC Filing  
11/3/2014Keith R LeonardCEOSell5,865$34.95$204,981.75View SEC Filing  
11/3/2014Nathaniel E DavidDirectorSell1,610$34.90$56,189.00View SEC Filing  
10/23/2014Keith R LeonardCEOSell1,913$35.13$67,203.69View SEC Filing  
10/1/2014Keith R LeonardCEOSell3,826$32.55$124,536.30View SEC Filing  
10/1/2014Nathaniel E DavidDirectorSell1,350$32.60$44,010.00View SEC Filing  
9/2/2014Nathaniel E DavidDirectorSell1,540$37.37$57,549.80View SEC Filing  
8/4/2014Keith R LeonardCEOSell1,828$35.10$64,162.80View SEC Filing  
8/4/2014Nathaniel E DavidDirectorSell1,505$33.08$49,785.40View SEC Filing  
8/1/2014Keith R LeonardCEOSell3,656$32.80$119,916.80View SEC Filing  
7/2/2014John W SmitherCFOSell2,250$40.00$90,000.00View SEC Filing  
7/2/2014Keith R LeonardCEOSell8,925$39.47$352,269.75View SEC Filing  
7/2/2014Nathaniel E DavidDirectorSell1,778$39.20$69,697.60View SEC Filing  
6/16/2014Keith R LeonardCEOSell1,743$36.58$63,758.94View SEC Filing  
6/2/2014Keith R LeonardCEOSell3,486$32.54$113,434.44View SEC Filing  
6/2/2014Nathaniel E DavidDirectorSell1,230$32.56$40,048.80View SEC Filing  
5/1/2014Keith LeonardCEOSell3,400$32.56$110,704.00View SEC Filing  
5/1/2014Nathaniel DavidDirectorSell1,200$32.60$39,120.00View SEC Filing  
4/1/2014Jeffrey WebsterVPSell4,000$39.36$157,440.00View SEC Filing  
4/1/2014Keith LeonardCEOSell13,260$39.08$518,200.80View SEC Filing  
3/20/2014John SmitherCFOSell1,125$43.78$49,252.50View SEC Filing  
3/3/2014Jeffrey WebsterVPSell4,000$49.55$198,200.00View SEC Filing  
3/3/2014Nathaniel DavidDirectorSell5,099$49.18$250,768.82View SEC Filing  
2/20/2014John SmitherCFOSell2,250$49.75$111,937.50View SEC Filing  
2/14/2014John SmitherCFOSell1,125$50.00$56,250.00View SEC Filing  
2/3/2014Jeffrey WebsterVPSell4,000$45.40$181,600.00View SEC Filing  
2/3/2014Keith LeonardCEOSell12,740$45.35$577,759.00View SEC Filing  
2/3/2014Nathaniel DavidDirectorSell5,000$45.31$226,550.00View SEC Filing  
1/21/2014John SmitherCFOSell1,125$42.54$47,857.50View SEC Filing  
1/2/2014Jeffrey WebsterVPSell4,000$37.38$149,520.00View SEC Filing  
1/2/2014Keith LeonardCEOSell12,480$37.38$466,502.40View SEC Filing  
12/2/2013Jeffrey WebsterVPSell4,000$38.69$154,760.00View SEC Filing  
12/2/2013Keith LeonardCEOSell12,220$38.95$475,969.00View SEC Filing  
12/2/2013Nathaniel DavidDirectorSell4,800$38.72$185,856.00View SEC Filing  
11/1/2013Jeffrey D WebsterVPSell4,000$44.90$179,600.00View SEC Filing  
11/1/2013Keith R LeonardCEOSell11,960$44.22$528,871.20View SEC Filing  
11/1/2013Nathaniel E DavidDirectorSell4,698$43.93$206,383.14View SEC Filing  
9/16/2013Keith LeonardCEOSell2,860$33.62$96,153.20View SEC Filing  
9/10/2013John W SmitherCFOSell40,000$30.02$1,200,800.00View SEC Filing  
9/10/2013Keith KleinGeneral CounselSell4,500$32.00$144,000.00View SEC Filing  
9/10/2013Nathaniel E DavidDirectorSell6,376$31.00$197,656.00View SEC Filing  
9/3/2013Jeffrey WebsterVPSell4,000$26.11$104,440.00View SEC Filing  
9/3/2013Keith LeonardCEOSell8,580$26.12$224,109.60View SEC Filing  
9/3/2013Nathaniel DavidDirectorSell3,375$26.12$88,155.00View SEC Filing  
8/1/2013Jeffrey D WebsterVPSell4,000$26.76$107,040.00View SEC Filing  
8/1/2013John W SmitherCFOSell10,000$26.80$268,000.00View SEC Filing  
8/1/2013Keith R LeonardCEOSell8,385$26.73$224,131.05View SEC Filing  
8/1/2013Nathaniel E DavidDirectorSell3,301$26.76$88,334.76View SEC Filing  
7/15/2013Keith R LeonardCEOSell1,365$28.90$39,448.50View SEC Filing  
7/1/2013Jeffrey D WebsterVPSell4,000$27.06$108,240.00View SEC Filing  
7/1/2013Keith R LeonardCEOSell8,190$27.10$221,949.00View SEC Filing  
7/1/2013Nathaniel E DavidDirectorSell3,225$27.07$87,300.75View SEC Filing  
6/28/2013Keith KleinGeneral CounselSell4,500$27.00$121,500.00View SEC Filing  
6/17/2013John W SmitherCFOSell6,000$26.00$156,000.00View SEC Filing  
6/17/2013Keith R LeonardCEOSell1,332$25.69$34,219.08View SEC Filing  
6/17/2013Nathaniel E DavidDirectorSell1,538$26.00$39,988.00View SEC Filing  
6/7/2013Jeffrey D WebsterVPSell4,000$25.00$100,000.00View SEC Filing  
6/3/2013Keith R LeonardCEOSell6,663$21.25$141,588.75View SEC Filing  
5/31/2013Jeffrey D WebsterVPSell4,000$22.26$89,040.00View SEC Filing  
5/1/2013Nathaniel E DavidDirectorSell2,625$21.42$56,227.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kythera Biopharmaceuticals (NASDAQ:KYTH)
DateHeadline
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Latest Broker Coverage - NewsDen (NASDAQ:KYTH)
newsden.net - September 29 at 5:50 PM
News IconBroker Roundup For Kythera Biopharmaceuticals, Inc. (NASDAQ ... - The De Soto Edge (NASDAQ:KYTH)
desotoedge.com - September 29 at 5:50 PM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M - REBusinessOnline (NASDAQ:KYTH)
rebusinessonline.com - September 1 at 8:56 AM
News IconIMT Westlake Village Apartment Complex in Los Angeles Sells for $88.2M (NASDAQ:KYTH)
rebusinessonline.com - August 31 at 10:43 AM
News Icon$88.25 Million Ventura County Multifamily Sale Closed by Marcus & Millichaps IPA Division (NASDAQ:KYTH)
www.cbs58.com - August 30 at 5:55 PM
News IconMedical Aesthetics Market Worth $69786 Million by 2021 - MENAFN.COM (NASDAQ:KYTH)
www.menafn.com - August 11 at 6:09 PM
bizjournals.com logoMedical Aesthetics Market Worth $69,786 Million by 2021 (NASDAQ:KYTH)
www.bizjournals.com - August 10 at 8:52 AM
News IconTeva/Actavis merger's FTC scrutiny creates another pharma winner - BioWorld Online (NASDAQ:KYTH)
www.bioworld.com - August 4 at 6:14 PM
streetinsider.com logoMannKind (MNKD) Assumes Responsibility for Distribution of Afrezza; Launches Patient Reimbursement Programs - StreetInsider.com (NASDAQ:KYTH)
www.streetinsider.com - August 1 at 5:45 PM
finance.yahoo.com logoMannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs (NASDAQ:KYTH)
finance.yahoo.com - August 1 at 10:38 AM
businesswire.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Business Wire (press release) (NASDAQ:KYTH)
www.businesswire.com - July 13 at 6:17 PM
tmcnet.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing (NASDAQ:KYTH)
www.tmcnet.com - July 13 at 8:52 AM
finance.yahoo.com logoSienna Biopharmaceuticals Announces Second Closing of Series A Financing - Yahoo Finance (NASDAQ:KYTH)
finance.yahoo.com - July 12 at 6:09 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Fiscal Standard (NASDAQ:KYTH)
www.fiscalstandard.com - July 3 at 5:27 PM
prnewswire.com logoSanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary - PR Newswire (press release) (NASDAQ:KYTH)
www.prnewswire.com - June 7 at 8:29 AM
News IconLatest Analyst Ratings For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Share Trading News (NASDAQ:KYTH)
www.sharetrading.news - May 20 at 8:00 PM
seekingalpha.com logoArena Q1: A Beat And A New CEO - Seeking Alpha (NASDAQ:KYTH)
seekingalpha.com - May 10 at 8:36 PM
prnewswire.com logoSanifit Expands Board With Senior Hire - PR Newswire (press release) (NASDAQ:KYTH)
www.prnewswire.com - May 10 at 8:36 PM
news.sys-con.com logoArena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer - SYS-CON Media (press release) (NASDAQ:KYTH)
news.sys-con.com - May 10 at 1:22 AM
streetinsider.com logoArena Pharma (ARNA) Taps Epirus Biopharma's Munshi as CEO - StreetInsider.com (NASDAQ:KYTH)
www.streetinsider.com - May 10 at 1:22 AM
investopedia.com logo6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE) (NASDAQ:KYTH)
www.investopedia.com - May 1 at 10:39 AM
News IconARCH leads $34 mln Series A financing in Sienna Biopharmaceuticals - Thomson Reuters' peHUB (press release) (NASDAQ:KYTH)
www.pehub.com - April 29 at 8:59 PM
businesswire.com logoSienna Biopharmaceuticals Announces $34 Million Series A Financing - Business Wire (press release) (NASDAQ:KYTH)
www.businesswire.com - April 28 at 9:55 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:KYTH)
www.sharetrading.news - April 24 at 10:58 PM
News IconMore fat profits? The makers of Botox say they have a cure for your double chin (NASDAQ:KYTH)
www.scmp.com - April 21 at 2:59 AM
bloomberg.com logoCompany Overview of Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)
www.bloomberg.com - April 18 at 2:31 AM
News IconBroker Roundup For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Share Trading News (NASDAQ:KYTH)
www.sharetrading.news - April 15 at 9:53 PM
News IconBroker Changes For Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) - Risers & Fallers (NASDAQ:KYTH)
www.risersandfallers.com - April 8 at 10:46 PM
News IconInstitutional Investor's Anti-Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) Sentiment In 2015 Q3 - Stock Caller (NASDAQ:KYTH)
www.stockcaller.com - April 7 at 11:07 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Updated Broker Price Targets - Share Trading News (NASDAQ:KYTH)
www.sharetrading.news - April 5 at 9:19 PM
News IconKythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Analyst Price Target Changes - Share Trading News (NASDAQ:KYTH)
www.sharetrading.news - April 3 at 7:58 PM
News IconLeerink Swann verifies KYTHERA BIOPHARMACEUTICALS INC (NASDAQ:KYTH) standing of Downgrade - Hints News Network (NASDAQ:KYTH)
hintsnewsnetwork.com - March 31 at 8:11 PM
insidermonkey.com logoIs Ellie Mae Inc (ELLI) A Good Stock To Buy? (NASDAQ:KYTH)
www.insidermonkey.com - December 1 at 4:38 PM
insidermonkey.com logoShould You Buy Kennametal Inc. (KMT)? (NASDAQ:KYTH)
www.insidermonkey.com - November 27 at 3:46 PM
noodls.com logoAllergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin (NASDAQ:KYTH)
www.noodls.com - October 8 at 9:54 AM
noodls.com logoKYTHERA® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss (NASDAQ:KYTH)
www.noodls.com - October 8 at 9:54 AM
finance.yahoo.com logoALLERGAN PLC. Financials (NASDAQ:KYTH)
finance.yahoo.com - October 6 at 1:04 PM
finance.yahoo.com logoXBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps (NASDAQ:KYTH)
finance.yahoo.com - October 2 at 4:07 PM
capitalcube.com logoKYTHERA Biopharmaceuticals, Inc. Earnings Q2, 2015 (NASDAQ:KYTH)
www.capitalcube.com - October 2 at 10:55 AM
biz.yahoo.com logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acqu (NASDAQ:KYTH)
biz.yahoo.com - October 1 at 4:24 PM
biz.yahoo.com logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:KYTH)
biz.yahoo.com - September 28 at 4:07 PM
finance.yahoo.com logoKYTHERA Files IND Application for Male Hair Loss Treatment (NASDAQ:KYTH)
finance.yahoo.com - September 23 at 5:05 PM
noodls.com logoKYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss (NASDAQ:KYTH)
www.noodls.com - September 22 at 9:25 AM
finance.yahoo.com logoKYTHERA Files Regulatory Application for Kybella in EU (NASDAQ:KYTH)
finance.yahoo.com - August 19 at 4:30 PM
biz.yahoo.com logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KYTH)
biz.yahoo.com - August 18 at 4:33 PM
noodls.com logoKYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat (NASDAQ:KYTH)
www.noodls.com - August 18 at 9:22 AM
biz.yahoo.com logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (NASDAQ:KYTH)
biz.yahoo.com - August 6 at 4:07 PM
finance.yahoo.com logoAllergan reports better-than-expected revenue (NASDAQ:KYTH)
finance.yahoo.com - August 6 at 9:33 AM
finance.yahoo.com logoWhat to Expect From Allergan Earnings (NASDAQ:KYTH)
finance.yahoo.com - August 5 at 2:05 PM
biz.yahoo.com logoKYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financia (NASDAQ:KYTH)
biz.yahoo.com - August 5 at 8:18 AM

Social

Kythera Biopharmaceuticals (NASDAQ:KYTH) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff